Science

$Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas$

Justin Stebbing/healthpost.in

Jan 29, 2025, 07:24

Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas

Justin Stebbing, Professor of Biomedical Sciences at Anglia Ruskin University (ARU), shared his recent article on LinkedIn:

“Thanks to an amazing team and remarkable drugs, an Fc-enhanced CTLA-4 and anti-PD1, showing an impressive response rate and duration of response in heavily pre-treated sarcoma at Agenus, with special thanks to Robin Jones, Breelyn Wilky, Joseph Grossman and Steven O’Day.”

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Authors: Breelyn A. Wilky, et al.

$Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas$

Agenus Anglia Ruskin University ARU Balstilimab botensilimab Breelyn A. Wilky Breelyn Wilky cancer CTLA-4 fight against cancer Global fight against cancer Joseph Grossman Justin Stebbing Metastatic Sarcomas OncoDaily Oncology Robin Jones Steven O'Day

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial